Sobi has announced the presentation of Phase 3 VALIANT data concerning Aspaveli® in nephrology at the upcoming American Society of Nephrology (ASN) meeting. Following the presentation, Sobi will host a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT to discuss the results and insights from the VALIANT trial. This call is intended for investors, analysts, and members of the media.
The conference call will feature a presentation of the VALIANT trial data by Sobi's management and Professor Fadi Fakhouri, followed by a question-and-answer session. Interested parties can access the live webcast of the presentation or view it later on Sobi's website. Presentation slides will also be available for download on sobi.com before the call.
To participate in the conference call, dial-in numbers are provided for Sweden (+46 8 5051 0031), the United Kingdom (+44 207 107 06 13), and the United States (+1 631 570 56 13). Dial-in details for other countries can be found on the provided link.
Sobi is a specialized international biopharmaceutical company focused on transforming the lives of individuals with rare and debilitating diseases. The company provides access to innovative medicines in hematology, immunology, and specialty care. With approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia, Sobi reported revenue of SEK 22.1 billion in 2023. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm.
About Aspaveli
Aspaveli (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the alternative complement pathway, which plays a role in several rare and severe diseases. The VALIANT trial is evaluating Aspaveli in a specific nephrology indication, with the aim of addressing unmet needs in patients with significant kidney dysfunction.
